Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SRPT 
Sarepta Therapeutics Inc (SRPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SRPT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $48.04
Year Target Price $48.04
| 14 | Strong Buy |
| 8 | Buy |
| 4 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.44% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.68B USD | Price to earnings Ratio - | 1Y Target Price 48.04 |
Price to earnings Ratio - | 1Y Target Price 48.04 | ||
Volume (30-day avg) 26 | Beta 0.6 | 52 Weeks Range 16.96 - 156.70 | Updated Date 06/30/2025 |
52 Weeks Range 16.96 - 156.70 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -11.12% | Operating Margin (TTM) -40.33% |
Management Effectiveness
Return on Assets (TTM) -2.19% | Return on Equity (TTM) -23.61% |
Valuation
Trailing PE - | Forward PE 9.84 | Enterprise Value 2500541476 | Price to Sales(TTM) 0.75 |
Enterprise Value 2500541476 | Price to Sales(TTM) 0.75 | ||
Enterprise Value to Revenue 1.12 | Enterprise Value to EBITDA 99.06 | Shares Outstanding 98277000 | Shares Floating 93857514 |
Shares Outstanding 98277000 | Shares Floating 93857514 | ||
Percent Insiders 4.44 | Percent Institutions 90.25 |
Analyst Ratings
Rating 5 | Target Price 48.04 | Buy 8 | Strong Buy 14 |
Buy 8 | Strong Buy 14 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sarepta Therapeutics Inc
Company Overview
History and Background
Sarepta Therapeutics Inc. was founded in 1980 as AntiVirals, Inc. and later changed its name to Sarepta in 2012. It is focused on developing RNA-targeted therapeutics for rare diseases, primarily Duchenne muscular dystrophy (DMD).
Core Business Areas
- Duchenne Muscular Dystrophy (DMD): Sarepta develops and commercializes therapies for treating Duchenne muscular dystrophy (DMD). This includes exon-skipping therapies and gene therapy approaches.
- Genetic Diseases: Expanding pipeline into other genetic diseases, including Limb-girdle muscular dystrophy (LGMD) and other neuromuscular disorders.
Leadership and Structure
The leadership team includes Douglas S. Ingram (President and CEO). The company is structured around research & development, commercial operations, and manufacturing.
Top Products and Market Share
Key Offerings
- Exondys 51 (eteplirsen): Exondys 51 is an exon-skipping drug targeting DMD patients amenable to exon 51 skipping. While specific market share data is unavailable, it was the first approved exon-skipping drug for DMD. Competitors include NS Pharma's Viltolarsen and Amondys 45.
- Amondys 45 (casimersen): Amondys 45 is another exon-skipping drug for DMD patients amenable to exon 45 skipping. Specific market share data is unavailable. It faces competition from NS Pharma and other potential gene therapies.
- Vyondys 53 (golodirsen): Vyondys 53 is an exon-skipping drug for DMD patients amenable to exon 53 skipping. Specific market share data is unavailable. It competes with other DMD therapies and potential gene therapies.
- Elevidys (delandistrogene moxeparvovec-rokl): Elevidys is a gene therapy for ambulatory DMD patients aged 4-5. Revenue from this product is in early stages of market introduction. Competitors are still emerging but include potentially other gene therapy approaches in the future
Market Dynamics
Industry Overview
The industry is characterized by high unmet needs in rare diseases, particularly in neuromuscular disorders. It is driven by advancements in genetic therapies and RNA-targeted approaches. Regulatory pathways are often accelerated due to the urgency of these diseases.
Positioning
Sarepta is a leader in developing RNA-targeted therapies for DMD. Its competitive advantage lies in its established portfolio of exon-skipping drugs and its early entry into DMD gene therapy.
Total Addressable Market (TAM)
The total addressable market for DMD therapies is estimated to be in the billions of dollars annually. Sarepta is well-positioned to capture a significant portion of this TAM with its portfolio of approved therapies and pipeline products.
Upturn SWOT Analysis
Strengths
- Early mover advantage in DMD therapies
- Established portfolio of approved products
- Strong focus on RNA-targeted approaches
- Gene therapy platform
Weaknesses
- High development costs
- Regulatory uncertainties
- Dependence on DMD market
- Reimbursement challenges for expensive therapies
Opportunities
- Expanding pipeline into other genetic diseases
- Developing next-generation RNA-targeted therapies
- Partnering with other companies to expand market reach
- Acquiring complementary technologies or companies
Threats
- Competition from other companies developing DMD therapies
- Potential safety issues with RNA-targeted therapies
- Changes in regulatory environment
- Pricing pressures from payers
Competitors and Market Share
Key Competitors
- VTRS
- PFE
- BMY
Competitive Landscape
Sarepta has a strong position in the DMD market, but faces increasing competition. Its advantage lies in its established portfolio and gene therapy platform. The competitors advantages are in size and legacy
Major Acquisitions
Lysogene
- Year: 2023
- Acquisition Price (USD millions): 53.4
- Strategic Rationale: Expand gene therapy capabilities and pipeline in central nervous system (CNS) disorders.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by regulatory approvals and commercial launches of DMD therapies.
Future Projections: Future growth is projected to be driven by continued commercialization of DMD therapies and expansion into new indications.
Recent Initiatives: Recent initiatives include the launch of Elevidys, expansion of the gene therapy pipeline, and strategic partnerships.
Summary
Sarepta Therapeutics is a strong player in the rare disease market, especially in DMD, due to its early market presence and focus on RNA-targeted therapies and gene therapy. Its approved drugs drive revenue, but high R&D costs affect profitability. Sarepta needs to manage competition, reimbursement challenges, and regulatory uncertainties while expanding into new genetic diseases to sustain growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Sarepta Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share figures are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sarepta Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1997-06-03 | President, CEO & Director Mr. Douglas S. Ingram Esq. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1372 | Website https://www.sarepta.com |
Full time employees 1372 | Website https://www.sarepta.com | ||
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.